SquareMind
"Redefined skin exams."
French medical robotics startup developing Swan, the world's first full-body dermoscopy robot combining a robotic arm, AI, and high-resolution imaging.
SquareMind is a Paris, France-based medical robotics company founded in 2019 by Ali Khachlouf and Tanguy Serrat.
The company has developed Swan™, the world's first robot designed to perform standardized, full-body dermoscopic skin imaging. Swan uses a robotic arm that moves autonomously around a standing patient in a private exam room, guided by visual and audio prompts, to capture dermoscopic-resolution images of the entire skin surface in just a few minutes. The system provides full-body skin mapping at a level of magnification typically achieved only when dermatologists examine individual moles up close, acting as an augmented dermatoscope for systematic, contactless, whole-body assessment. Swan is paired with an AI platform that supports change detection, tracking lesions and moles over time to assist dermatologists in identifying abnormalities earlier. The device is FDA-listed and CE-marked. In April 2026, SquareMind closed an $18 million funding round (approximately €15.3 million) to support commercial launch of Swan in the United States and Europe. The round was led by Sonder Capital — a California-based healthcare venture fund co-founded by Intuitive Surgical founder Fred Moll — with participation from the French government's Deeptech 2030 Fund managed by Bpifrance, Adamed Technology, Calm/Storm Ventures, and Teampact Ventures.
The company operates in both France and the United States and can be reached at [email protected]. SquareMind's mission is to make high-quality, consistent skin exams more efficient and accessible at scale.
Primary type & automation activities this supplier delivers:
Swan Full-Body Dermoscopy Robot
- Model: Swan
- Launch Year: 2026
The world's first robotic system for automated full-body dermoscopic skin imaging, FDA-listed and CE-marked, with AI-powered lesion change detection.
Contact SquareMind
WEBSITE
https://www.squaremind.com/HEADQUARTERS
France
Company Facts
Founded
2019
Primary Role
Manufacturer
Company Size
-
Primary Region
Europe
Annual Sales
-
Funding Stage
-
Funding Total
-
Certifications & Memberships
Keywords
- SquareMind
- medical robot
- dermoscopy
- skin imaging
- AI diagnosis
- healthcare robotics
- FDA-listed
- CE-marked
- dermoscopy robot
- full-body skin imaging
- AI dermatology
- skin cancer detection
- Swan robot
- healthcare AI
- dermatological imaging
- Manufacturer
- Software/Algorithm
- Commercial Service Robot
- Perception & Vision
- Industrial Robot
ROBOTTODAY Weekly April 27th – May 1st, 2026
This week in robotics: Figure scales to one humanoid per hour, Meta acquires Assured Robot Intelligence, China's State Grid commits $995M for 8,500 AI robots, and SoftBank plans $100B IPO for robotics spinout Roze. April 28–May 2, 2026.
SquareMind raises $18M for robotic dermatology platform
Squaremind has successfully secured $18 million in funding to develop Swan, an innovative robotic platform designed to automate full-body skin imaging aimed at early cancer detection. This significant investment will enable the company to enhance its technology, which is poised to improve diagnostic accuracy and efficiency in dermatology. The funding round reflects a growing interest in advanced medical technologies that leverage robotics and artificial intelligence to address critical healthcare challenges. By streamlining the imaging process, Swan aims to facilitate timely interventions for skin cancer, ultimately contributing to better patient outcomes.
Artificial Intelligence Cobot Arms Healthcare Robotics News Squaremind
SquareMind Raises $18M in Funding to Launch AI-Driven Robotic Skin Imaging Platform in US and Europe
SquareMind, a medical robotics company based in France, has successfully secured $18 million in funding, which includes previously undisclosed pre-Series A financing. This investment, primarily led by Sonder Capital, a California-based venture fund co-founded by Fred Moll, comes as SquareMind gears up to launch its innovative robotic skin imaging platform aimed at dermatology practices. The company plans to introduce this technology in both the United States and Europe, enhancing diagnostic capabilities in the field. The funding will support the final stages of development and facilitate the market entry of this cutting-edge solution, addressing the growing demand for advanced dermatological tools.
AI AI Funding & Investment Robotics France funding medical robotics
